|Videos|July 5, 2023
Future Perspectives on the Role of Bispecifics in MM
Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
4
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
5